Innate Pharma (IPHA) Liabilities and Shareholders Equity (2017 - 2025)

Innate Pharma has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $73.0 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 38.48% year-over-year to $73.0 million; the trailing twelve-month figure through Dec 2025 stood at $460.0 million (down 33.04% YoY), and the FY2025 full-year result was $73.0 million, down 38.48% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $73.0 million, down from $105.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $320.6 million in Q2 2021, with the low at $73.0 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $200.3 million across 5 years, with a median of $200.3 million in 2022.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity sank 99.9% — and 2022, when it declined 6.66%.
• Innate Pharma's Liabilities and Shareholders Equity stood at $306.0 million in 2021, then plunged by 30.7% to $212.1 million in 2022, then decreased by 11.12% to $188.5 million in 2023, then sank by 37.04% to $118.7 million in 2024, then slumped by 38.48% to $73.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $73.0 million (Q4 2025), $105.2 million (Q2 2025), and $118.7 million (Q4 2024), per Business Quant data.